$32.62
0.42% today
Nasdaq, May 02, 06:19 pm CET
ISIN
GB00BMVP7Y09
Symbol
RPRX
Sector
Industry

Royalty Pharma plc - Ordinary Shares - Class A Stock price

$32.48
+1.31 4.20% 1M
+5.38 19.85% 6M
+6.97 27.32% YTD
+4.41 15.71% 1Y
-9.87 23.31% 3Y
-12.02 27.01% 5Y
-12.02 27.01% 10Y
Nasdaq, Closing price Thu, May 01 2025
-0.34 1.04%
ISIN
GB00BMVP7Y09
Symbol
RPRX
Sector
Industry

Key metrics

Market capitalization $14.08b
Enterprise Value $24.10b
P/E (TTM) P/E ratio 16.94
EV/FCF (TTM) EV/FCF 8.63
EV/Sales (TTM) EV/Sales 10.64
P/S ratio (TTM) P/S ratio 6.22
P/B ratio (TTM) P/B ratio 2.09
Dividend yield 2.59%
Last dividend (FY24) $0.84
Revenue growth (TTM) Revenue growth -3.85%
Revenue (TTM) Revenue $2.26b
EBIT (operating result TTM) EBIT $1.29b
Free Cash Flow (TTM) Free Cash Flow $2.79b
Cash position $987.23m
EPS (TTM) EPS $1.92
P/E forward 23.20
P/S forward 4.68
EV/Sales forward 8.01
Short interest 4.82%
Show more

Is Royalty Pharma plc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,792 stocks worldwide.

Royalty Pharma plc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:

Buy
75%
Hold
25%

Financial data from Royalty Pharma plc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2,264 2,264
4% 4%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 970 970
20% 20%
43%
- Research and Development Expense 2.50 2.50
95% 95%
0%
1,292 1,292
13% 13%
57%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 1,292 1,292
13% 13%
57%
Net Profit 859 859
24% 24%
38%

In millions USD.

Don't miss a Thing! We will send you all news about Royalty Pharma plc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Royalty Pharma plc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
11 days ago
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share.
Neutral
GlobeNewsWire
15 days ago
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day.
Neutral
GlobeNewsWire
24 days ago
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic are...
More Royalty Pharma plc - Ordinary Shares - Class A News

Company Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.

Head office United Kingdom
CEO Pablo Legorreta
Employees 99
Founded 1996
Website royaltypharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today